Three-Year Progression-Free Survival of Metastatic Breast Cancer Treated With the Palbociclib and Letrozole Combination

被引：0
|
作者：
Karam, Imad [1 ]
Nair, Hari [2 ]
Ghani, Sofia [3 ]
Khalid, Bilal [3 ]
机构：
[1] St Lukes Hosp, PGY II Internal Med, Saginaw, MI USA
[2] St Louis Univ Hosp, PGY V Hematol & Oncol, St Louis, MI 63104 USA
[3] St Louis Univ Hosp, St Louis, MI USA
来源：
AMERICAN JOURNAL OF THERAPEUTICS | 2023年 / 30卷 / 04期
关键词：
D O I：
10.1097/MJT.0000000000001484
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：E408 / E410
页数：3
相关论文
共 50 条
  • [41] Progression-free survival benefits in triple negative breast cancer
    Fricker, Janet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (11) : 610 - 610
  • [42] A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503
    Innocenti, Federico
    Owzar, Kouros
    Jiang, Chen
    Sibley, Alexander
    Mulkey, Flora
    Carey, Lisa A.
    Tripathy, Debu
    Schneider, Bryan P.
    Barry, William Thomas
    Winer, Eric P.
    Hudis, Clifford A.
    McLeod, Howard L.
    Dickler, Maura N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Progression-free survival as endpoint in metastatic RCC?
    Knox, Jennifer J.
    LANCET, 2008, 372 (9637): : 427 - 429
  • [44] Progression-free survival in metastatic, BRAF-mutated colorectal cancer
    Morris, Van Karlyle
    Overman, Michael J.
    Maru, Dipen M.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [45] Comment on "Rucaparib extends progression-free survival in metastatic prostate cancer"
    von Amsberg, Gunhild
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (21) : 1340 - 1341
  • [46] Overall and progression-free survival in metastatic basosquamous cancer: A case series
    Zhu, Gefei Alex
    Danial, Christina
    Liu, Andy
    Li, Shufeng
    Chang, Anne Lynn Su
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (06) : 1145 - 1146
  • [47] Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer
    Mehmet Ali Nahit Şendur
    Dogan Uncu
    Nurullah Zengin
    Medical Oncology, 2014, 31
  • [48] Circulating Tumor Cells in Metastatic Breast Cancer: Monitoring Response to Chemotherapy and Predicting Progression-Free Survival
    Cheng, Jian-ping
    Yan, Ying
    Wang, Xiang-yi
    Lu, Yuan-li
    Yuan, Yan-hua
    Wang, Xiao-li
    Jia, Jun
    Ren, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (03) : 201 - 210
  • [49] Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Halabi, Susan
    Roy, Akash
    Rydzewska, Larysa
    Guo, Siyuan
    Godolphin, Peter
    Hussain, Maha
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael A.
    Smith, Matthew R.
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    James, Nick
    Buyse, Marc E.
    Tierney, Jayne F.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09)
  • [50] The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
    Ziegler, Philipp
    Hartkopf, Andreas D.
    Wallwiener, Markus
    Haeberle, Lothar
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Ettl, Johannes
    Lueftner, Diana
    Mueller, Volkmar
    Michel, Laura L.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Huebner, Hanna
    Uhrig, Sabrina
    Wurmthaler, Lena A.
    Hack, Carolin C.
    Mundhenke, Christoph
    Kurbacher, Christian
    Fasching, Peter A.
    Wuerstlein, Rachel
    Untch, Michael
    Janni, Wolfgang
    Taran, Florin-Andrei
    Lux, Michael P.
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Fehm, Tanja N.
    Schneeweiss, Andreas
    Goossens, Chloe
    BMC CANCER, 2024, 24 (01)
12345